Understanding the side effects of glucocorticoid therapy: Shining a light on a drug everyone thinks they know

Annals of the Rheumatic Diseases

Volumn 71, Issue 11, 2012, Pages 1761-1764

  Dixon, William G ^a   Bansback, Nick ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PRODUCT; GENERIC DRUG; GLUCOCORTICOID; METHOTREXATE;

ADRENAL INSUFFICIENCY; ADVERSE DRUG REACTION; CARDIOVASCULAR DISEASE; CATARACT; CORTICOSTEROID THERAPY; DIABETES MELLITUS; DISEASE SEVERITY; DRUG RESEARCH; DRUG SAFETY; GLAUCOMA; HIGH RISK PATIENT; HUMAN; LOW DRUG DOSE; MEDICAL DECISION MAKING; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PROBABILITY; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

ANTI-INFLAMMATORY AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOCORTICOIDS; HEALTH COMMUNICATION; HUMANS; PATIENT MEDICATION KNOWLEDGE; RISK ASSESSMENT; TIME FACTORS;

EID: 84867404783     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202021     Document Type: Review

References (35)

1. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004;141:764-70.
2. Walsh LJ, Wong CA, Pringle M, et al. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ 1996;313:344-6. (Pubitemid 26334822)
3. Caplan L, Wolfe F, Russell AS, et al. Corticosteroid use in rheumatoid arthritis: prevalence, predictors, correlates, and outcomes. J Rheumatol 2007;34:696-705. (Pubitemid 46641373)
4. National Institute of H, Clinical E. NICE clinical guideline 79. Rheumatoid arthritis. The management of rheumatoid arthritis in adults, 2009.
5. Van Staa TP, Leufkens HG, Abenhaim L, et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 2000; 39:1383-9. (Pubitemid 32045866)
6. Hench PS, Kendall EC, Slocumb CH, et al. Effects of cortisone acetate and pituitary acth on rheumatoid arthritis, rheumatic fever and certain other conditions - a study in clinical physiology. Arch Intern Med 1950; 85:545-666.
7. Dixon WG, Suissa S, Hudson M. The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses. Arthritis Res Ther 2011;13 :R139.
8. Conn DL. Resolved: low-dose prednisone is indicated as a standard treatment in patients with rheumatoid arthritis. Arthritis Rheum 2001; 45:462-7. (Pubitemid 32979852)
9. Saag KG. Resolved: low-dose glucocorticoids are neither safe nor effective for the long-term treatment of rheumatoid arthritis. Arthritis Rheum 2001;45 :468-71. (Pubitemid 32979853)
10. Akhavan PS, Hazlewood GS, Sun Y, et al. Factors affecting glucocorticoid use in early rheumatoid arthritis. Results from an early arthritis cohort. Arthritis Rheum 2011; 63(Suppl):A1198.
11. Criswell LA, Such CL, Yelin EH. Differences in the use of second-line agents and prednisone for treatment of rheumatoid arthritis by rheumatologists and non-rheumatologists. J Rheumatol 1997;24:2283-90. (Pubitemid 28005123)
12. Morrison E, Crosbie D, Capell HA. Attitude of rheumatoid arthritis patients to treatment with oral corticosteroids. Rheumatology (Oxford) 2003;42 :1247-50. (Pubitemid 37258490)
13. Herxheimer A. Communicating with patients about harms and risks. PLoS Med 2005; 2:e42.
14. Hoes JN, Jacobs JW, Boers M, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2007;66:1560-7. (Pubitemid 350205441)
15. van der Goes MC, Jacobs JW, Boers M, et al. Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis 2010;69 :1913-9.
16. Solomon DH, Love TJ, Canning C, et al. Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis and psoriasis. Ann Rheum Dis 2010;69:2114-17.
17. Hoes JN, van der Goes MC, van Raalte DH, et al. Glucose tolerance, insulin sensitivity and {beta}-cell function in patients with rheumatoid arthritis treated with or without low-to-medium dose glucocorticoids. Ann Rheum Dis 2011;70:1887-94.
18. Di Comite G, Rossi CM. Risk of diabetes in patients with rheumatoid arthritis taking hydroxychloroquine. JAMA 2007;298:2368-9; author reply 69-70.
19. Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002;96:23- 43.
20. Hetland ML, Ostergaard M, Ejbjerg B, et al. Short- and long-term efficacy of intra-articular injections with betamethasone as part of a treat-to-target strategy in early rheumatoid arthritis: impact of joint area, repeated injections, MRI findings, anti-CCP, IgM-RF and CRP. Ann Rheum Dis 2012;71:851-6.
21. LaRochelle GE Jr, LaRochelle AG, Ratner RE, et al. Recovery of the hypothalamic-pituitary-adrenal (HPA) axis in patients with rheumatic diseases receiving low-dose prednisone. Am J Med 1993; 95:258-64. (Pubitemid 23270282)
22. Eddy DM. Clinical decision making: from theory to practice. Anatomy of a decision. JAMA: J Am Med Assoc 1990;263:441-3.
23. van der Goes MC, Jacobs JW, Boers MA, et al. Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2010;69:1015-21.
24. Merlino LA, Bagchi I, Taylor TN, et al. Preference for fractures and other glucocorticoid-associated adverse effects among rheumatoid arthritis patients. Med Decis Making 2001;21:122-32. (Pubitemid 32318763)
25. Bowling A, Ebrahim S. Measuring patients' preferences for treatment and perceptions of risk. Qual Health Care 2001;10(Suppl 1):i2-8. (Pubitemid 32844120)
26. Bakker MF, Jacobs JW, Welsing PM, et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med 2012;156:329-39.
27. Basch E. Patient-reported outcomes in drug safety evaluation. Ann Oncol 2009; 20:1905-6.
28. Dixon WG, Abrahamowicz M, Beauchamp ME, et al. Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis. Ann Rheum Dis 2012; 71:1128-33.
29. Thamer M, Hernan MA, Zhang Y, et al. Prednisone, lupus activity, and permanent organ damage. J Rheumatol 2009;36:560-4.
30. Newman MA, Ziebland S, Barker KL. Patients' views of a multimedia resource featuring experiences of rheumatoid arthritis: pilot evaluation of www. healthtalkonline.org. Health Informatics J 2009;15:147-59.
31. Edwards A, Elwyn G. Shared decision-making in health care. 2nd edn. Oxford, UK: Oxford University Press, 2009.
32. Kaptchuk TJ. Effect of interpretive bias on research evidence. BMJ 2003;326:1453-5. (Pubitemid 36776160)
33. McMaster A, Ray DW. Drug insight: selective agonists and antagonists of the glucocorticoid receptor. Nat Clin Pract Endocrinol Metab 2008;4:91-101. (Pubitemid 351156903)
34. Buttgereit F, Doering G, Schaeffler A, et al. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet 2008;371:205-14.
35. Buttgereit F, Mehta D, Kirwan J, et al. Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). Ann Rheum Dis 2012. Published Online First: 5 May 2012. doi:10.1136/annrheumdis-2011-201067.